Tiziana Life Sciences Ltd filed a Form 6-K with the SEC on November 9, 2026, furnishing additional context on positive topline results from its Phase 2a INFORM-MS trial following a Key Opinion Leader investor call held the same day.

Key Highlights

  • INFORM-MS dual primary endpoints: According to the filing, the Phase 2a INFORM-MS trial achieved dual primary endpoint success, as reviewed during the November 9, 2026 KOL call.
  • Principal investigators featured: The filing identifies Tanuja Chitnis, M.D., Tarun Singhal, MBBS, M.D., M.B.A., and Howard L. Weiner, M.D. as presenters on the KOL call.
  • Exhibits furnished: A press release (Exhibit 99.1) and a presentation (Exhibit 99.2), both dated November 9, 2026, were furnished as part of this report.
  • Not filed for liability purposes: The filing states the exhibits "shall not be deemed 'filed' for the purposes of Section 18 of the Securities Exchange Act of 1934."
  • Signed by CFO: The report was signed by Keeren Shah, Chief Financial Officer, on November 9, 2026.

Tiziana Life Sciences Provides INFORM-MS Trial Context After KOL Call

Tiziana Life Sciences Ltd (Commission File Number 001-38723) submitted a Form 6-K on November 9, 2026, disclosing additional context surrounding positive topline results from its Phase 2a INFORM-MS trial. The report follows a Key Opinion Leader investor call held on Monday, November 9, 2026, described in the filing as "highly engaged."

According to the filing, the KOL call featured three principal investigators: Tanuja Chitnis, M.D., Tarun Singhal, MBBS, M.D., M.B.A., and Howard L. Weiner, M.D. The filing states the call "reviewed the dual primary endpoint success of INFORM-MS and generated strong participation from the investment and scientific communities." The company is a foreign private issuer incorporated in the United Kingdom, with its principal executive office located at 9th Floor, 107 Cheapside, London, EC2V 6DN, and files annual reports under Form 20-F.

The substantive disclosures referenced in the 6-K are contained in two exhibits furnished with the report: Exhibit 99.1, described as a press release dated November 9, 2026, and Exhibit 99.2, described as a presentation dated November 9, 2026. The filing explicitly states these exhibits are furnished, not filed, and are therefore not subject to the liabilities of Section 18 of the Securities Exchange Act of 1934. The report was authorized and signed by Chief Financial Officer Keeren Shah.

What Was Disclosed

Tiziana Life Sciences filed a Form 6-K on November 9, 2026, furnishing a press release and presentation providing additional context on INFORM-MS Phase 2a trial results, following a KOL investor call featuring three named principal investigators that same day.